Diabetes & Endocrinology – Page 8

Once-Weekly Insulin GZR4: A Potential Paradigm Shift in Basal Insulin Therapy for Type 2 Diabetes

By MedXY 02/04/2026

A Phase 1b trial demonstrates that the once-weekly insulin GZR4 is safe, well-tolerated, and effective in lowering FPG and HbA1c in patients with T2DM, potentially offering a more convenient alternative to daily basal insulin.

Cardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

By MedXY 02/04/2026

This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a critical adjunctive therapy in metabolic-arrhythmic management.

Diabetes & Endocrinology Internal Medicine news

Beyond Glycemic Control: How SGLT2 and DPP-4 Inhibitor Combinations Rescue the Urinary Microbiome in Type 2 Diabetes

By MedXY 02/04/2026

A new study reveals that combining Empagliflozin with Linagliptin reverses urinary dysbiosis in T2D patients, potentially reducing the risk of urogenital infections and improving treatment adherence compared to SGLT2 inhibitor monotherapy.

Diabetes & Endocrinology news Public Health

Challenging Public Health Dogma: Six Months of Low Sweet Taste Exposure Fails to Shift Preference or Weight

By MedXY 02/04/2026

The Sweet Tooth Trial reveals that reducing dietary sweet exposure for six months does not decrease sweet taste liking, calorie intake, or weight, questioning the efficacy of current public health strategies centered solely on reducing sweet-tasting food exposure.

Cardiology Diabetes & Endocrinology news

Circadian Heart Rate Fluctuations: A Potent 21-Year Predictor of Mortality in Patients with Diabetes

By MedXY 02/04/2026

A 21-year longitudinal study demonstrates that impaired circadian heart rate fluctuations, measured via 24-hour ambulatory monitoring, significantly predict cardiovascular and all-cause mortality in diabetes, offering a low-cost, accessible tool for identifying high-risk patients.

Cardiology Diabetes & Endocrinology news

Haptoglobin Levels and Phenotype as Determinants of Cardiovascular Risk in Type 2 Diabetes: Insights from the FIELD Sub-study

By MedXY 02/04/2026

This FIELD sub-study reveals that while Haptoglobin 1-1 phenotype combined with low HP levels indicates the lowest CVD risk in Type 2 Diabetes, higher HP levels significantly increase risk, particularly within the HP 1-1 group. Fenofibrate benefits appear independent of HP status.

Cardiology Diabetes & Endocrinology news

Beyond Blood Sugar: Why Insulin Resistance Drives Vagal Dysfunction in Heart Failure

By MedXY 02/04/2026

Evidence from the Myovasc study reveals that insulin resistance and C-peptide levels are independent predictors of impaired cardiac vagal activity in heart failure, suggesting that metabolic health directly influences autonomic regulation beyond simple glycemic control.

Diabetes & Endocrinology Internal Medicine news

Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D

By MedXY 02/04/2026

A post-hoc analysis demonstrates that baseline insulin secretion identifies responders to abatacept in Stage 1 T1D. High-secretors experienced a 15.8-month delay in disease progression and a 54% reduction in risk, providing the first evidence of successful immune intervention in the earliest stage of the disease.

Diabetes & Endocrinology Nephrology news

Beyond Glycemic Control: Empagliflozin/Linagliptin Combination Restores Urinary Microbiota Homeostasis in Type 2 Diabetes

By MedXY 02/03/2026

A randomized clinical study demonstrates that while SGLT2 inhibitors alone may induce urinary dysbiosis and increase pathogen risk, combining them with DPP-4 inhibitors restores a healthy urinary microbiota, potentially improving patient compliance and long-term therapeutic outcomes.

Cardiology Diabetes & Endocrinology news

Diminished Circadian Heart Rate Fluctuations: A Potent Predictor of 21-Year Mortality in Patients with Diabetes

By MedXY 02/03/2026

A 21-year longitudinal study reveals that blunted circadian heart rate variability and nocturnal dipping are independent predictors of cardiovascular and all-cause mortality in type 1 and type 2 diabetes, offering a low-cost risk stratification tool via ambulatory monitoring.

Cardiology Diabetes & Endocrinology news

Haptoglobin 1-1 and Low Protein Levels: Identifying the Lowest Cardiovascular Risk in Type 2 Diabetes

By MedXY 02/03/2026

A FIELD sub-study reveals that while higher haptoglobin levels increase cardiovascular risk—particularly in those with the HP 1-1 phenotype—fenofibrate's protective effects remain consistent regardless of haptoglobin status, challenging previous assumptions about phenotype-specific treatment responses.

Cardiology Diabetes & Endocrinology news

Insulin Metabolism as a Primary Driver of Cardiac Autonomic Dysfunction in Heart Failure: Insights from the Myovasc Study

By MedXY 02/03/2026

The Myovasc study demonstrates that insulin resistance and secretion markers, rather than glucose levels alone, are independently associated with impaired cardiac vagal activity in heart failure patients, suggesting a metabolic-autonomic axis that requires targeted clinical attention.

Diabetes & Endocrinology news

Precision Immunotherapy in Type 1 Diabetes: Baseline Beta-Cell Function as a Predictive Biomarker for Abatacept Efficacy

By MedXY 02/03/2026

A post-hoc analysis reveals that Abatacept significantly delays progression to Stage 2 or 3 Type 1 Diabetes specifically in individuals with higher baseline insulin secretion, marking a breakthrough in precision immunotherapy for early-stage disease.

Diabetes & Endocrinology news

Behavioral Diet Therapy Achieves Superior Postprandial Glycemic Control Over Gastric Bypass Despite Equivalent Weight Loss

By MedXY 02/03/2026

A dual-tracer study reveals that behavioral diet therapy provides greater postprandial glycemic improvement than Roux-en-Y gastric bypass after 20% weight loss in people with type 2 diabetes, driven by enhanced insulin-mediated glucose disposal unique to the dietary intervention.

Diabetes & Endocrinology news Ophthalmology

Evening Chronotype Linked to Progression of Diabetic Retinopathy and Poor Metabolic Control

By MedXY 02/03/2026

Recent longitudinal and cross-sectional data reveal that patients with an evening chronotype face significantly higher risks of diabetic retinopathy and metabolic dysregulation, independent of traditional glycemic markers like HbA1c.

Diabetes & Endocrinology Nephrology news

Precision Medicine Outperforms Standard Albuminuria Thresholds for SGLT2 Inhibitor Selection in Type 2 Diabetes

By MedXY 02/03/2026

A new precision medicine model identifies high-benefit patients for SGLT2 inhibitor treatment even when albumin levels appear normal, potentially preventing 10% more kidney failure events than current guidelines that rely solely on albuminuria thresholds.

Diabetes & Endocrinology Nephrology news

GLP-1 Receptor Agonists Significantly Reduce MACE Risk Across the CKD Spectrum, Yet Prescription Rates Remain Suboptimal

By MedXY 02/03/2026

Recent data highlights that GLP-1 receptor agonists (GLP1-RAs) reduce cardiovascular risk in patients with chronic kidney disease (CKD), yet real-world prescription rates remain alarmingly low despite these proven benefits across various stages of renal impairment.

Cardiology Diabetes & Endocrinology news

Type 1 Diabetes Confers Double the Risk of Coronary Stent Failure Compared to Non-Diabetics: A SWEDEHEART Analysis

By MedXY 02/02/2026

A nationwide SWEDEHEART study reveals that while second-generation drug-eluting stents have improved outcomes, patients with Type 1 and Type 2 diabetes remain at significantly higher risk for stent failure, with Type 1 patients facing a more than twofold increased risk.

Cardiology Diabetes & Endocrinology news

Beyond Weight Loss: CagriSema Emerges as a Potent Antihypertensive in Obesity Management

By MedXY 02/02/2026

The REDEFINE 1 trial demonstrates that CagriSema, a semaglutide/cagrilintide combination, significantly reduces blood pressure in adults with overweight or obesity, even among those with resistant hypertension, while facilitating the reduction of concomitant antihypertensive medications.

Diabetes & Endocrinology Internal Medicine news

Substituting Water for Artificially Sweetened Beverages Fails to Improve Glycemic Control in Type 2 Diabetes: Results from the SODAS Trial

By MedXY 02/02/2026

The Study of Drinks with Artificial Sweeteners (SODAS) randomized trial reveals that replacing habitual artificially sweetened beverages with water does not improve HbA1c levels in patients with type 2 diabetes, with the water group surprisingly showing higher HbA1c levels than the beverage group.